Drugs / T-DEN-Post-Transfection F19
last change Apr 2010 re-read 3 minutes ago

T-DEN-Post-Transfection F19

Vaccine

Developed for
dengue shock syndrome
Investigated by
GlaxoSmithKline · U.S. Army Medical Research and Development Command

Trials 1

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00468858 Jul 2007 → Apr 2010 dengue shock syndrome U.S. Army Medical Research and Development Command Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as T-DEN-Post-Transfection F19 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00468858 ↗
Modality Vaccine “investigational dengue vaccine (T-DEN)” NCT00468858 ↗